BBIO
BEARISH
$77.87
Live
BridgeBio Pharma, Inc. · NASDAQ
Target $89.79
(+15.3%)
$28.32
52W Range
$81.33
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$14.92B
P/E
N/A
ROE
N/A
Profit margin
-225.3%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
The company exhibits extremely weak fundamental health with a Piotroski F-Score of just 1/9, indicating severe financial distress. Despite explosive revenue growth of 4318% YoY and strong analyst recommendation of 'strong_buy', profitability remains deeply negative with operating and net margins at -112.97% and -225.32% respectively. Insider selling is aggressively bearish, with $56.6M in sales over the last six months and zero buys, contradicting the bullish analyst stance. While liquidity ratios are healthy (Current Ratio: 3.88), the lack of Altman Z-Score and negative valuation metrics suggest high risk and speculative pricing not supported by earnings or cash flow.
Key Strengths
Exceptional year-over-year revenue growth of 4318.00% indicates strong commercial or pipeline momentum
High gross margin of 95.78% suggests scalable business model and pricing power
Strong analyst consensus with 'strong_buy' rating from 19 analysts
Healthy liquidity position with Current Ratio of 3.88 and Quick Ratio of 3.52
Recent positive EPS trends showing YoY improvement of +33.3% and Q/Q growth of +24.2%
Key Risks
Critically low Piotroski F-Score of 1/9 signals severe financial weakness and poor earnings quality
Massive insider selling: $56.6M in sales over 6 months with no insider buying, indicating lack of confidence from executives
Negative profitability across all metrics: ROA at -43.48%, Operating Margin at -112.97%, and Profit Margin at -225.32%
Valuation metrics are deeply negative: Forward P/E of -43.91 and Price/Book of -7.76, indicating no earnings or book value support
Absence of Altman Z-Score prevents bankruptcy risk assessment, but negative equity and earnings suggest potential distress
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
10
75
40
15
0
AI Verdict
High-risk speculative biotech with unsustainable fundamentals despite growth
Key drivers: Piotroski F-Score of 1 severely penalizes health, Insider selling contradicts analyst optimism, Negative profitability and valuation metrics, Exceptional revenue growth provides upside potential, Liquidity buffers reduce near-term solvency risk
Confidence
78%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 42.18 may be justified in high-growth biotech
Watchpoints
- Forward P/E of -43.91 indicates no earnings
- Price/Book of -7.76 shows negative equity
- Graham Number is $None — no defensive value
Future
75/100
Ref Growth rates
Positives
- Revenue Growth (YoY): 4318.00%
- EPS YoY Growth: +33.3%
- EPS Q/Q Growth: +24.2%
Watchpoints
- Earnings growth unstable and negative in absolute terms
- No Forward EBITDA or cash flow guidance
Past
40/100
Ref Historical trends
Positives
- Recent quarters show improving EPS trends
- Some earnings beats in history (e.g., +77% in Q1 2024)
Watchpoints
- Average earnings surprise over last 4 quarters: -16.17%
- Consistent negative earnings and misses since 2020
- Only 2 out of last 4 quarters beat estimates
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio: 3.88
- Quick Ratio: 3.52
Watchpoints
- Piotroski F-Score: 1/9 (Weak)
- Altman Z-Score: None (Unassessable, but likely distressed)
- ROA: -43.48%
- Debt/Equity: N/A (likely negative equity)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$77.87
Analyst Target
$89.79
Upside/Downside
+15.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BBIO and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharma, Inc.
Primary
|
+18.4% | +720.5% | +110.0% | +68.2% | +1.8% | +2.1% |
|
MEDP
Medpace Holdings, Inc.
Peer
|
+174.6% | +172.4% | +78.2% | -5.6% | +12.7% | -1.0% |
|
PODD
Insulet Corporation
Peer
|
-28.4% | -37.3% | -19.6% | -36.3% | -12.6% | +1.0% |
|
RGC
Regencell Bioscience Holdings Limited
Peer
|
+10275.8% | +3861.7% | +3641.3% | +64.7% | +8.7% | -0.5% |
|
ASND
Ascendis Pharma A/S
Peer
|
+53.7% | +106.6% | +48.4% | +15.5% | +2.0% | -6.1% |
BBI
BridgeBio Pharma, Inc.
Primary
5Y
+18.4%
3Y
+720.5%
1Y
+110.0%
6M
+68.2%
1M
+1.8%
1W
+2.1%
MED
Medpace Holdings, Inc.
Peer
5Y
+174.6%
3Y
+172.4%
1Y
+78.2%
6M
-5.6%
1M
+12.7%
1W
-1.0%
POD
Insulet Corporation
Peer
5Y
-28.4%
3Y
-37.3%
1Y
-19.6%
6M
-36.3%
1M
-12.6%
1W
+1.0%
RGC
Regencell Bioscience Holdings Limited
Peer
5Y
+10275.8%
3Y
+3861.7%
1Y
+3641.3%
6M
+64.7%
1M
+8.7%
1W
-0.5%
ASN
Ascendis Pharma A/S
Peer
5Y
+53.7%
3Y
+106.6%
1Y
+48.4%
6M
+15.5%
1M
+2.0%
1W
-6.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-43.91
PEG Ratio
N/A
P/B Ratio
-7.76
P/S Ratio
42.18
EV/Revenue
45.88
EV/EBITDA
-28.32
Market Cap
$14.92B
Profitability
Profit margins and return metrics
Profit Margin
-225.32%
Operating Margin
-112.97%
Gross Margin
95.78%
ROE
N/A
ROA
-43.48%
Growth
Revenue and earnings growth rates
Revenue Growth
+4318.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
3.88
Strong
Quick Ratio
3.52
Excellent
Cash/Share
$3.35
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-19
$N/A
2025-10-29
$-0.72
+7.7% surprise
2025-08-05
$-0.95
-57.1% surprise
2025-04-29
$-0.99
+0.9% surprise
Healthcare Sector Comparison
Comparing BBIO against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Profit Margin
-225.32%
This Stock
vs
-16.28%
Sector Avg
+1284.0%
(Superior)
Revenue Growth
4318.0%
This Stock
vs
124.04%
Sector Avg
+3381.1%
(Fast Growth)
Current Ratio
3.88
This Stock
vs
4.47
Sector Avg
-13.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharma, Inc.
|
BEARISH | $14.92B | - | -% | -225.3% | $77.87 | |
|
MEDP
Medpace Holdings, Inc.
|
NEUTRAL | $14.7B | 34.6 | 70.2% | 17.8% | $514.9 | Compare |
|
PODD
Insulet Corporation
|
NEUTRAL | $14.18B | 57.73 | 18.1% | 9.1% | $201.47 | Compare |
|
RGC
Regencell Bioscience...
|
BEARISH | $14.18B | - | -54.8% | -% | $28.67 | Compare |
|
ASND
Ascendis Pharma A/S
|
BULLISH | $13.87B | - | -% | -31.7% | $225.98 | Compare |
BBIO
BridgeBio Pharma, Inc.
BEARISH
Mkt Cap
$14.9B
P/E
-
ROE
-%
Price
$77.87
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-09 | KUMAR NEIL | Chief Executive Officer | Sale | 80,000 | $6,043,168 |
| 2025-12-15 | KUMAR NEIL | Chief Executive Officer | Sale | 30,011 | $2,239,902 |
| 2025-12-12 | KUMAR NEIL | Chief Executive Officer | Stock Award | 60,975 | - |
| 2025-12-08 | APULI MARICEL | Officer | Sale | 2,000 | $148,520 |
| 2025-12-05 | KUMAR NEIL | Chief Executive Officer | Sale | 80,000 | $5,908,476 |
| 2025-11-20 | KUMAR NEIL | Chief Executive Officer | Sale | 26,156 | $1,722,224 |
| 2025-11-18 | LO ANDREW W. | Director | Sale | 95,599 | $6,319,662 |
| 2025-11-17 | SCOTT RANDAL W | Director | Sale | 10,000 | $666,465 |
| 2025-11-17 | TRIMARCHI THOMAS | President | Sale | 16,934 | $1,125,404 |
| 2025-11-17 | SCOTT RANDAL W | Director | Option Exercise | 10,000 | $167,500 |
| 2025-11-14 | KUMAR NEIL | Chief Executive Officer | Stock Award | 64,697 | - |
| 2025-11-12 | VALANTINE HANNAH A. | Director | Sale | 25,484 | $1,683,728 |
| 2025-11-12 | VALANTINE HANNAH A. | Director | Option Exercise | 25,484 | $1,234,700 |
| 2025-11-07 | KUMAR NEIL | Chief Executive Officer | Sale | 80,000 | $4,983,111 |
| 2025-11-06 | DANIELS RONALD J | Director | Sale | 61,031 | $3,888,999 |
KUMAR NEIL
Chief Executive Officer
2026-01-09
80,000 shares
·
$6,043,168
KUMAR NEIL
Chief Executive Officer
2025-12-15
30,011 shares
·
$2,239,902
KUMAR NEIL
Chief Executive Officer
2025-12-12
60,975 shares
APULI MARICEL
Officer
2025-12-08
2,000 shares
·
$148,520
KUMAR NEIL
Chief Executive Officer
2025-12-05
80,000 shares
·
$5,908,476
KUMAR NEIL
Chief Executive Officer
2025-11-20
26,156 shares
·
$1,722,224
LO ANDREW W.
Director
2025-11-18
95,599 shares
·
$6,319,662
SCOTT RANDAL W
Director
2025-11-17
10,000 shares
·
$666,465
TRIMARCHI THOMAS
President
2025-11-17
16,934 shares
·
$1,125,404
SCOTT RANDAL W
Director
2025-11-17
10,000 shares
·
$167,500
KUMAR NEIL
Chief Executive Officer
2025-11-14
64,697 shares
VALANTINE HANNAH A.
Director
2025-11-12
25,484 shares
·
$1,683,728
VALANTINE HANNAH A.
Director
2025-11-12
25,484 shares
·
$1,234,700
KUMAR NEIL
Chief Executive Officer
2025-11-07
80,000 shares
·
$4,983,111
DANIELS RONALD J
Director
2025-11-06
61,031 shares
·
$3,888,999
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
19 analysts
Wells Fargo
2026-01-20
Overweight
Overweight
Truist Securities
2026-01-08
Buy
Buy
Morgan Stanley
2026-01-06
Overweight
Leerink Partners
2025-12-15
Outperform
Outperform
Bernstein
2025-12-11
Outperform
Wells Fargo
2025-11-11
Overweight
Overweight
JP Morgan
2025-11-07
Overweight
Overweight
HC Wainwright & Co.
2025-11-03
Buy
Buy
Goldman Sachs
2025-10-31
Buy
Buy
TD Cowen
2025-10-30
Buy
Buy
Past News Coverage
Recent headlines mentioning BBIO from our newsroom.
Newest → oldest
No matching news yet.